intertrochanteric fracture
Conditions
Interventions
A:100ml tranexamic acid sodium chloride injection was injected intravenously 5 minutes before surgery. After the completion of pulp dilation and before insertion of intramedullary nail, 50 mL carbamat
B:100ml (1g) of tranexamic acid sodium chloride injection was given intravenously 5 minutes before surgery. After intraoperative pulpal dilation was completed and before intramedullary nail was insert
C:Tranexamic acid sodium chloride injection 100ml (1g) was injected intravenously 5 minutes before surgery. After the pulpal redilation was completed and before intramedullary nail was inserted, 50 mL
D:100ml of tranexamic acid sodium chloride injection (1g) was given intravenously 5 minutes before surgery. After pulpal dilation and before intramedullary nail insertion, 50 mL of 0.9% sodium chlorid
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 90 Years
Inclusion criteria
Inclusion criteria: ? Patients with imaging diagnosis of femoral intertrochanteric fracture requiring unilateral PFNA surgery; ? Body mass index (BMI20-35kg/m2) ? The preoperative ASA classification was grade I-III ? Age 60 and above ? There were no significant abnormalities in hemoglobin, coagulation and liver and kidney function before operation.
Exclusion criteria
Exclusion criteria: ? Allergic to tranexamic acid, carbalosulfonate sodium, anesthetic drugs ? non-simple intertrochanteric fracture; Alcoholic or pregnant persons; ? Use anticoagulant drugs or birth control pills 5 days before surgery; ? Old fracture History of thromboembolic disease (i.e., deep vein thrombosis (DVT), or pulmonary embolism (PE)), clotting disease, recent arterial thromboembolic events (e.g., myocardial infarction or stroke), hypercoagulability, hemophilia; Severe cardiovascular and respiratory diseases; Kidney and liver failure, history of kidney transplantation; ? with severe bleeding disease ? Those who refuse to participate in or accept blood products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Blood Loss; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative Blood Loss;Hidden Blood Loss;Transfusion rate ;mean operating time;Mean blood pressure;inflammatory makers;VAS score;hospital stays;coagulation indicator;The rate of vein thrombosis ; | — |
Countries
China
Contacts
Public ContactLihan Shi
Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed